[Skip to Content]
[Skip to Content Landing]
Views 1,578
Citations 0
Editorial
April 7, 2020

Treatment for Advanced Soft Tissue Sarcoma: An Informative Neutral Trial

Author Affiliations
  • 1Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston
  • 2Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
  • 3Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire
JAMA. 2020;323(13):1251-1252. doi:10.1001/jama.2020.0567

The treatment of soft tissue sarcomas (STSs), which encompass a group of more than 70 histologically and biologically distinct subtypes of cancer, is emblematic of an orphan disease.1 About 13 000 patients are diagnosed as having STS in the United States every year,2 survival rates are poor and have not changed in the last 40 years, and there is little funding to support scientific discovery of disease biology to improve treatment regimens. Clinical presentation and prognosis are influenced not only by the extent of disease and histological subtypes, but by tumor location as well. There is a significant unmet need for improved systemic therapies in the treatment of patients with STS.

×